Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00838305 · ClinicalTrials.gov registry record · NA
Role of Serotonin in Acute and Subacute MDMA Effects
A NA study, sponsored by California Pacific Medical Center Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT00838305 is a NA study that has completed, run by California Pacific Medical Center Research Institute. The registered enrollment target is 13 participants.
The verdict
NCT00838305, a NA study, has completed, sponsored by California Pacific Medical Center Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to measure the effects of MDMA (particularly its emotional effects) and to determine the role of serotonin in these effects. Serotonin is a neurotransmitter, which is a chemical that is released by some brain cells to communicate with other brain cells. Many of the effects of MDMA are thought to be the result of increased serotonin release. In order to understand the effects of MDMA and role of serotonin in these effects, we will administer MDMA alone and in combination with the antidepressant citalopram (one trade name for this is Celexa). Citalopram decreases the ability of MDMA to release serotonin. Citalopram will therefore decrease any of MDMA's effects that are the result of serotonin release; we want to measure this.
Interventions
- DRUG Placebo
- DRUG MDMA and citalopram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2009-02 |
| Est. Completion | 2011-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00838305
The ClinicalTrials.gov registry entry for NCT00838305 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is California Pacific Medical Center Research Institute, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00838305 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00838305 about?
NCT00838305 is a clinical study titled "Role of Serotonin in Acute and Subacute MDMA Effects". The purpose of this study is to measure the effects of MDMA (particularly its emotional effects) and to determine the role of serotonin in these effects. Serotonin is a neurotransmitter, which is a chemical that is released by some brain cells to communicate with other brain cells. Many of the effec...
What is the current status of trial NCT00838305?
This trial is currently completed. It is a NA study. The enrollment target is 13 participants. The study started on 2009-02. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00838305?
The interventions under investigation include: Placebo (DRUG), MDMA and citalopram (DRUG).
Who is sponsoring clinical trial NCT00838305?
This trial is sponsored by California Pacific Medical Center Research Institute, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.